Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket StudyYoshiaki Nakamura, Tanios Bekaii‐Saab, Yu Sunakawa et al.|Journal of Clinical Oncology|2023Cited by 100
The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA MutationJu Sun Kim, Seung Tae Kim|Journal of Cancer|2017Cited by 17
Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutationTaehyang Lee, Seung Tae Kim|Journal of Cancer|2018Cited by 6